DEXCOM INC Form 8-K June 04, 2018

### **UNITED STATES**

### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### FORM 8-K

## **CURRENT REPORT**

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 31, 2018

DexCom, Inc.

(Exact Name of the Registrant as Specified in Its Charter)

**Delaware** 

(State or Other Jurisdiction of Incorporation)

000-51222 (Commission File Number) 33-0857544 (IRS Employer Identification No.)

## Edgar Filing: DEXCOM INC - Form 8-K

6340 Sequence Drive, San Diego, CA (Address of Principal Executive Offices)

92121 (Zip Code)

(858) 200-0200

(Registrant s Telephone Number, Including Area Code)

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2)

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

## Item 5.07. Submission of Matters to a Vote of Security Holders.

73,284,816

Nicholas Augustinos

- (a) DexCom held its Annual Meeting on May 31, 2018. Proxies for the Annual Meeting were solicited pursuant to Regulation 14A of the Securities Exchange Act of 1934, as amended. At the close of business on the record date, there were 88,074,614 shares outstanding and entitled to vote and 81,867,004 shares were voted in person or by proxy on the matters described below.
- (b) The matters described below were voted on at the Annual Meeting and the number of votes cast with respect to each matter was as indicated:
- (1) Holders of DexCom s common stock voted to elect three Class I directors, each to serve until their successor has been elected and qualified or until their earlier resignation or removal as follows:

						Abstentions		
		For (%)		Against (%)		(%)		
		(excluding		(excluding		(excluding		
		broker		broker		broker		
Name	For (#)	non-votes)	Against (#)	non-votes)A	bstentions (	#non-votes)Bro	oker Non-Votes	
Terrance H. Gregg	73,196,817	98.10%	1,342,176	1.80%	72,064	0.10%	7,255,947	
Kevin Sayer	74,341,599	99.64%	198,470	0.27%	70,988	0.10%	7,255,947	

(2) Holders of DexCom s common stock voted to ratify the appointment of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2018:

1,255,076

1.68%

71,166

0.10%

7,255,946

98.22%

	<b>Number of Shares</b>	Percentage of Shares
Shares Voted in Favor:	81,130,290	99.10%
Shares Voted Against:	644,405	0.79%
Shares Abstaining:	92,309	0.11%

(3) Holders of DexCom s common stock voted to approve the non-binding advisory resolution on compensation paid to DexCom s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including compensation discussion and analysis, compensation tables and narrative discussion:

# **Percentage of Shares**

	<b>Number of Shares</b>	(excluding broker non-votes)
Shares Voted in Favor:	66,521,900	89.16%
Shares Voted Against:	8,001,213	10.72%
Shares Abstaining:	87,945	0.12%

# **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

# DEXCOM, INC.

By: <u>/s/ Steven R. Pacelli</u>

Steven R. Pacelli

Executive Vice President, Strategy and Corporate Development

Date: June 4, 2018